Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Down 32.2% in February

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 59,900 shares, a drop of 32.2% from the January 31st total of 88,400 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average trading volume of 55,200 shares, the days-to-cover ratio is presently 1.1 days.

Plus Therapeutics Price Performance

PSTV traded down $0.36 on Tuesday, reaching $0.30. 4,645,982 shares of the stock were exchanged, compared to its average volume of 190,859. The company’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.29. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The firm has a market capitalization of $1.78 million, a PE ratio of -0.12 and a beta of 0.70.

Analyst Ratings Changes

A number of research firms have recently weighed in on PSTV. Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.